Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs
藥企巨頭的豪賭:誰將主宰減肥市場?
The tussle between the two drugmakers has spread from the boardroom to the courtroom to the corridors of Washington
輝瑞與諾和諾德為爭奪生物科技公司Metsera展開激烈競購,報價飆升至100億美元。這場交易不僅涉及法庭訴訟和反壟斷審查,更觸及華盛頓政治圈,凸顯減肥藥物市場的巨大潛力和激烈競爭。